Title:
RETENTION OF ANTIGEN-BINDING MOLECULES IN BLOOD PLASMA AND METHOD FOR MODIFYING IMMUNOGENICITY
Document Type and Number:
WIPO Patent Application WO/2012/133782
Kind Code:
A1
Abstract:
The present invention involves the discovery that by modifying the Fc region of an antigen-binding molecule to an Fc region in which a heterocomplex containing a bimolecular FcRn and four activating Fcγ receptors does not form in the neutral pH range, pharmacokinetics improve due to the antigen-binding molecule, and immune response decreases due to the antigen-binding molecule. In addition, the present invention resulted in the discovery of a method for manufacturing antigen-binding molecules having the abovementioned characteristics, and also resulted in the discovery that when a drug composition, which contains such antigen-binding molecules or antigen-binding molecules manufactured according to the manufacturing method of the present invention as an active ingredient, is administered, the antigen-binding molecules have excellent characteristics, such as improving pharmacokinetics and decreasing immune response by a living organism that has been administered the drug, compared to antigen-binding molecules of the prior art.
Inventors:
IGAWA TOMOYUKI (JP)
MAEDA ATSUHIKO (JP)
HARAYA KENTA (JP)
IWAYANAGI YUKI (JP)
TACHIBANA TATSUHIKO (JP)
MIMOTO FUTA (JP)
KURAMOCHI TAICHI (JP)
KATADA HITOSHI (JP)
KADONO SHOJIRO (JP)
MAEDA ATSUHIKO (JP)
HARAYA KENTA (JP)
IWAYANAGI YUKI (JP)
TACHIBANA TATSUHIKO (JP)
MIMOTO FUTA (JP)
KURAMOCHI TAICHI (JP)
KATADA HITOSHI (JP)
KADONO SHOJIRO (JP)
Application Number:
PCT/JP2012/058603
Publication Date:
October 04, 2012
Filing Date:
March 30, 2012
Export Citation:
Assignee:
CHUGAI PHARMACEUTICAL CO LTD (JP)
IGAWA TOMOYUKI (JP)
MAEDA ATSUHIKO (JP)
HARAYA KENTA (JP)
IWAYANAGI YUKI (JP)
TACHIBANA TATSUHIKO (JP)
MIMOTO FUTA (JP)
KURAMOCHI TAICHI (JP)
KATADA HITOSHI (JP)
KADONO SHOJIRO (JP)
IGAWA TOMOYUKI (JP)
MAEDA ATSUHIKO (JP)
HARAYA KENTA (JP)
IWAYANAGI YUKI (JP)
TACHIBANA TATSUHIKO (JP)
MIMOTO FUTA (JP)
KURAMOCHI TAICHI (JP)
KATADA HITOSHI (JP)
KADONO SHOJIRO (JP)
International Classes:
C12N15/09; A61K39/395; C07K16/46; C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12P21/08
Domestic Patent References:
| WO2010058860A1 | 2010-05-27 | |||
| WO2003057881A1 | 2003-07-17 | |||
| WO2009125825A1 | 2009-10-15 | |||
| WO2000042072A2 | 2000-07-20 | |||
| WO2006019447A1 | 2006-02-23 | |||
| WO2004099249A2 | 2004-11-18 | |||
| WO2004029207A2 | 2004-04-08 | |||
| WO2004044011A2 | 2004-05-27 | |||
| WO2005040229A2 | 2005-05-06 | |||
| WO2002032925A2 | 2002-04-25 | |||
| WO1995001937A1 | 1995-01-19 | |||
| WO2002020565A2 | 2002-03-14 | |||
| WO2003029462A1 | 2003-04-10 | |||
| WO2008016854A2 | 2008-02-07 | |||
| WO2003000883A1 | 2003-01-03 | |||
| WO2004022754A1 | 2004-03-18 | |||
| WO2006006693A1 | 2006-01-19 | |||
| WO2003104453A1 | 2003-12-18 | |||
| WO1994011523A2 | 1994-05-26 | |||
| WO1996002576A1 | 1996-02-01 | |||
| WO1993012227A1 | 1993-06-24 | |||
| WO1992003918A1 | 1992-03-19 | |||
| WO1994002602A1 | 1994-02-03 | |||
| WO1994025585A1 | 1994-11-10 | |||
| WO1996034096A1 | 1996-10-31 | |||
| WO1996033735A1 | 1996-10-31 | |||
| WO1992001047A1 | 1992-01-23 | |||
| WO1992020791A1 | 1992-11-26 | |||
| WO1993006213A1 | 1993-04-01 | |||
| WO1993011236A1 | 1993-06-10 | |||
| WO1993019172A1 | 1993-09-30 | |||
| WO1995001438A1 | 1995-01-12 | |||
| WO1995015388A1 | 1995-06-08 | |||
| WO2008081008A1 | 2008-07-10 | |||
| WO2009086320A1 | 2009-07-09 | |||
| WO2008092117A2 | 2008-07-31 | |||
| WO2007041635A2 | 2007-04-12 | |||
| WO2006105338A2 | 2006-10-05 | |||
| WO1996027011A1 | 1996-09-06 | |||
| WO2006106905A1 | 2006-10-12 | |||
| WO2009041062A1 | 2009-04-02 | |||
| WO2010136598A1 | 2010-12-02 | |||
| WO2009139822A1 | 2009-11-19 |
Foreign References:
| JP2007532139A | 2007-11-15 | |||
| JPH02163085A | 1990-06-22 | |||
| JPH01144991A | 1989-06-07 | |||
| JPH02501112A | 1990-04-19 | |||
| JP2011184418A | 2011-09-22 | |||
| EP0239400A2 | 1987-09-30 | |||
| US20090035836A1 | 2009-02-05 | |||
| US20090136485A1 | 2009-05-28 |
Other References:
YEUNG Y.A. ET AL.: "Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates.", J. IMMUNOL., vol. 182, 15 June 2009 (2009-06-15), pages 7663 - 7671, XP002566420
DALL'ACQUA W.F. ET AL.: "Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences.", J. IMMUNOL., vol. 169, no. 9, 1 November 2002 (2002-11-01), pages 5171 - 5180, XP002268422
JANICE M REICHERT; CLARK J ROSENSWEIG; LAURA B FADEN; MATTHEW C DEWITZ: "Monoclonal antibody successes in the clinic.", NAT. BIOTECHNOL., vol. 23, 2005, pages 1073 - 1078
PAVLOU AK; BELSEY MJ.: "The therapeutic antibodies market to 2008.", EUR J PHARM BIOPHARM., vol. 59, no. 3, 2005, pages 389 - 396
KIM SJ; PARK Y; HONG HJ.: "Antibody engineering for the development of therapeutic antibodies.", MOL CELLS, vol. 20, no. 1, 2005, pages 17 - 29
HINTON PR; XIONG JM; JOHLFS MG; TANG MT; KELLER S; TSURUSHITA N.: "An engineered human IgGI antibody with longer serum half-life.", J. IMMUNOL., vol. 176, no. 1, 2006, pages 346 - 356
GHETIE V; POPOV S; BORVAK J; RADU C; MATESOI D; MEDESAN C; OBER RJ; WARD ES.: "Increasing the serum persistence of an IgG fragment by random mutagenesis.", NAT. BIOTECHNOL., vol. 15, no. 7, 1997, pages 637 - 640
RAJPAL A; BEYAZ N; HABER L; CAPPUCCILLI G; YEE H; BHATT RR; TAKEUCHI T; LERNER RA; CREA R.: "A general method for greatly improving the affinity of antibodies by using combinatorial libraries", PROC. NATL. ACAD. SCI. U. S. A., vol. 102, no. 24, 2005, pages 8466 - 8471
WU H; PFARR DS; JOHNSON S; BREWAH YA; WOODS RM; PATEL NK; WHITE WI; YOUNG JF; KIENER PA.: "Development of Motavizumab, an Ultra-potent Antibody for the Prevention of Respiratory Syncytial Virus Infection in the Upper and Lower Respiratory Tract.", J. MOL. BIOL., vol. 368, 2007, pages 652 - 665
HANSON CV; NISHIYAMA Y; PAUL S.: "Catalytic antibodies and their applications", CURR OPIN BIOTECHNOL., vol. 16, no. 6, 2005, pages 631 - 636
RATHANASWAMI P; ROALSTAD S; ROSKOS L; SU QJ; LACKIE S; BABCOOK J.: "Demonstration of an in vivo generated sub-picomolar affinity fully human monoclonal antibody to interleukin-8", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 334, no. 4, 2005, pages 1004 - 1013
DALL'ACQUA WF; WOODS RM; WARD ES; PALASZYNSKI SR; PATEL NK; BREWAH YA; WU H; KIENER PA; LANGERMANN S.: "Increasing the affinity of a human IgG for the neonatal Fc receptor: biological consequences", J. IMMUNOL., vol. 169, no. 9, 2002, pages 5171 - 5180
YEUNG YA; LEABMAN MK; MARVIN JS; QIU J; ADAMS CW; LIEN S; STAROVASNIK MA; LOWMAN HB.: "Engineering human IgGl affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates", J. IMMUNOL., vol. 182, no. 12, 2009, pages 7663 - 7671
DATTA-MANNAN A; WITCHER DR; TANG Y; WATKINS J; WROBLEWSKI VJ.: "Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor.", J. BIOL. CHEM., vol. 282, no. 3, 2007, pages 1709 - 1717
NIEBECKER R; KLOFT C.: "Safety of therapeutic monoclonal antibodies", CURR. DRUG SAF., vol. 5, no. 4, 2010, pages 275 - 286
JEFFERIS R; LUND J.: "Interaction sites on human IgG-Fc for FcgammaR: current models", IMMUNOL. LETT., vol. 82, 2002, pages 57 - 65
NIMMERJAHN F; RAVETCH JV: "Fcgamma receptors as regulators of immune responses", NAT. REV. IMMUNOL., vol. 8, no. 1, 2008, pages 34 - 47
M. CLARK: "Antibody Engineering IgG Effector Mechanisms", CHEMICAL IMMUNOLOGY, vol. 65, 1997, pages 88 - 110
GREENWOOD J; CLARK M; WALDMANN H.: "Structural motifs involved in human IgG antibody effector functions", EUR. J. IMMUNOL., vol. 23, 1993, pages 1098 - 1104
AMIGORENA S; BONNEROT C; CHOQUET D; FRIDMAN WH; TEILLAUD JL.: "Fc gamma RII expression in resting and activated B lymphocytes", EUR. J. IMMUNOL., vol. 19, 1989, pages 1379 - 1385
NICHOLAS R; SINCLAIR SC: "Regulation of the immune response. I. Reduction in ability of specific antibody to inhibit long-lasting IgG immunological priming after removal of the Fc fragment", J. EXP. MED., vol. 129, 1969, pages 1183 - 1201
HEYMAN B.: "Feedback regulation by IgG antibodies", IMMUNOL. LETT., vol. 88, 2003, pages 157 - 161
S AMIGORENA; C BONNEROT; DRAKE, JR; D CHOQUET; W HUNZIKER; JG GUILLET; P WEBSTER; C SAUTES; I MELLMAN; WH FRIDMAN: "Cytoplasmic domain heterogeneity and functions of IgG Fc receptors in B lymphocytes", SCIENCE, vol. 256, 1992, pages 1808 - 1812
MUTA, T.; KUROSAKI, T.; MISULOVIN, Z.; SANCHEZ, M.; NUSSENZWEIG, M. C.; RAVETCH, J. V: "A 13-amino-acid motif in the cytoplasmic domain ofFcyRIIB modulates B-cell receptor signaling", NATURE, vol. 368, 1994, pages 70 - 73
RAVETCH JV; LANIER LL.: "Immune inhibitory receptors", SCIENCE, vol. 290, 2000, pages 84 - 89
LIANG Y; QIU H; GLINKA Y; LAZARUS AH; NI H; PRUD'HOMME GJ; WANG Q.: "Immunity against a therapeutic xenoprotein/Fc construct delivered by gene transfer is reduced through binding to the inhibitory receptor FcyRIIb", J. GENE MED., 2011
SMITH KG; CLATWORTHY MR.: "FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications", NAT. REV. IMMUNOL., vol. 10, 2010, pages 328 - 343
WERNERSSON S; KARLSSON MC; DAHLSTROM J; MATTSSON R; VERBEEK JS; HEYMAN B.: "IgG-mediated enhancement of antibody responses is low in Fc receptor gamma chain-deficient mice and increased in Fc gamma RII-deficient mice", J. IMMUNOL., vol. 163, 1999, pages 618 - 622
JOACHIM L. SCHULTZE; SABINE MICHALAK; JOEL LOWNE; ADAM WONG; MARIA H. GILLEECE; JOHN G. GRIBBEN; LEE M. NADLER: "Human Non-Germinal Center B Cell Interleukin (IL)-12 Production Is Primarily Regulated by T Cell Signals CD40 Ligand, Interferon y, and IL-10: Role of B Cells in the Maintenance ofT Cell Responses", J. EXP. MED., vol. 189, 1999, pages 187 - 194
NAKAMURA, A.; YUASA, T.; UJIKE, A.; ONO, M.; NUKIWA, T.; RAVETCH, J.V; TAKAI, T.: "Fcy receptor IIB-deficient mice develop Goodpasture's syndrome upon immunization with type IV collagen: A novel murine model for autoimmune glomerular basement membrane disease", J. EXP. MED., vol. 191, 2000, pages 899 - 906
BLANK MC; STEFANESCU RN; MASUDA E; MARTI F; KING PD; REDECHA PB; WURZBURGER RJ; PETERSON MG; TANAKA S; PRICOP L.: "Decreased transcription of the human FCGR2B gene mediated by the -343 G/C promoter polymorphism and association with systemic lupus erythematosus", HUM. GENET., vol. 117, 2005, pages 220 - 227
OLFERIEV M; MASUDA E; TANAKA S; BLANK MC; PRICOP L.: "The Role of Activating Protein 1 in the Transcriptional Regulation of the Human FCGR2B Promoter Mediated by the -343 G ->C Polymorphism Associated with Systemic Lupus Erythematosus", J. BIOL. CHEM., vol. 282, 2007, pages 1738 - 1746
LV J; YANG Y; ZHOU X; YU L; LI R; HOU P; ZHANG H: "FCGR3B copy number variation is not associated with lupus nephritis in a Chinese population", ARTHRITIS RHEUM., vol. 54, 2006, pages 3908 - 3917
FLOTO RA; CLATWORTHY MR; HEILBRONN KR; ROSNER DR; MACARY PA; RANKIN A; LEHNER PJ; OUWEHAND WH; ALLEN JM; WATKINS NA: "Loss of function of a lupus-associated FcgammaRIIb polymorphism through exclusion from lipid rafts", NAT. MED., vol. 11, 2005, pages 1056 - 1058
LI DH; TUNG JW; TAMER IH; SNOW AL; YUKINARI T; NGERNMANEEPOTHONG R; MARTINEZ OM; PARNES JR.: "CD72 Down-Modulates BCR-Induced Signal Transduction and Diminishes Survival in Primary Mature B Lymphocytes", J. IMMUNOL., vol. 176, 2006, pages 5321 - 5328
MACKAY M; STANEVSKY A; WANG T; ARANOW C; LI M; KOENIG S; RAVETCH JV; DIAMOND B.: "Selective dysregulation of the FcgammaIIB receptor on memory B cells in SLE.", J. EXP. MED., vol. 203, 2006, pages 2157 - 2164
SU K; YANG H; LI X; LI X; GIBSON AW; CAFARDI JM; ZHOU T; EDBERG JC; KIMBERLY RP.: "Expression profile ofFcgammaRIIb on leukocytes and its dysregulation in systemic lupus erythematosus", J. IMMUNOL., vol. 178, 2007, pages 3272 - 3280
BRUHNS P; IANNASCOLI B; ENGLAND P; MANCARDI DA; FERNANDEZ N; JORIEUX S; DAËRON M.: "Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses", BLOOD, vol. 113, 2009, pages 3716
CHU SY; VOSTIAR I; KARKI S; MOORE GL; LAZAR GA; PONG E; JOYCE PF; SZYMKOWSKI DE; DESJARLAIS JR.: "Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD 19 and FcgammaRlIb with Fc-engineered antibodies", MOL. IMMUNOL., vol. 45, 2008, pages 3926 - 3933
WARMERDAM PA; VAN DE WINKEL JG; GOSSELIN EJ; CAPEL PJ.: "Molecular basis for a polymorphism of human Fc gamma receptor II (CD32", J. EXP. MED., vol. 172, 1990, pages 19 - 25
ARMOUR, KL; VAN DE WINKEL, JG; WILLIAMSON, LM; CLARK, MR.: "Differential binding to human FcgammaRIIa and FcgammaRIIb receptors by human IgG wildtype and mutant antibodies", MOL. IMMUNOL., vol. 40, 2003, pages 585 - 593
SCIENCE TRANSLATIONAL MEDICINE, vol. 2, no. 47, 2010, pages 47RA63
SALMON JE; MILLARD S; SCHACHTER LA; ARNETT FC; GINZLER EM; GOURLEY MF; RAMSEY-GOLDMAN R; PETERSON MG; KIMBERLY RP.: "Fc gamma RIIA alleles are heritable risk factors for lupus nephritis in African Americans", J. CLIN. INVEST., vol. 97, 1996, pages 1348 - 1354
MANGER K; REPP R; SPRIEWALD BM; RASCU A; GEIGER A; WASSMUTH R; WESTERDAAL NA; WENTZ B; MANGER B; KALDEN JR: "Fcgamma receptor IIa polymorphism in Caucasian patients with systemic lupus erythematosus: association with clinical symptoms", ARTHRITIS RHEUM., vol. 41, 1998, pages 1181 - 1189
QIAO SW; KOBAYASHI K; JOHANSEN FE; SOLLID LM; ANDERSEN JT; MILFORD E; ROOPENIAN DC; LENCER WI; BLUMBERG RS.: "Dependence of antibody-mediated presentation of antigen on FcRn.", PROC. NATL. ACAD. SCI., vol. 105, no. 27, 2008, pages 9337 - 9342
MI W; WANJIE S; LO ST; GAN Z; PICKL-HERK B; OBER RJ; WARD ES: "Targeting the neonatal fc receptor for antigen delivery using engineered fc fragments", J. IMMUNOL., vol. 181, no. 11, 2008, pages 7550 - 7561
"Epitope Mapping Protocols in Methods in Molecular Biology", vol. 66, 1996
ED HARLOW; DAVID LANE: "Antibodies: A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY, pages: 359 - 420
MULLBERG ET AL., J. IMMUNOL., vol. 152, no. 10, 1994, pages 4958 - 4968
SAMBROOK, J ET AL.: "Molecular Cloning", 1989, COLD SPRING HARBOR LAB. PRESS, pages: 9.47 - 9.58
J. IMMUNOL., vol. 123, no. 4, 1979, pages 1548 - 1550
CURRENT TOPICS IN MICROBIOLOGY AND IMMUNOLOGY, vol. 81, 1978, pages 1 - 7
C. EUR. J. IMMUNOL., vol. 6, no. 7, 1976, pages 511 - 519
CELL, vol. 8, no. 3, 1976, pages 405 - 415
NATURE, vol. 276, no. 5685, 1978, pages 269 - 270
J. IMMUNOL. METHODS, vol. 35, no. 1-2, 1980, pages 1 - 21
J. EXP. MED., vol. 148, no. 1, 1978, pages 313 - 323
NATURE, vol. 277, no. 5692, 1979, pages 131 - 133
KOHLER; MILSTEIN, METHODS ENZYMOL., vol. 73, 1981, pages 3 - 46
VANDAMME ET AL., EUR. J. BIOCHEM., vol. 192, no. 3, 1990, pages 767 - 775
BIOCHEMISTRY, vol. 18, no. 24, 1979, pages 5294 - 5299
ANAL. BIOCHEM., vol. 162, no. 1, 1987, pages 156 - 159
PROC. NATL. ACAD. SCI. USA, vol. 85, no. 23, 1988, pages 8998 - 9002
NUCLEIC ACIDS RES., vol. 17, no. 8, 1989, pages 2919 - 2932
EBERT, K. M. ET AL., BIO/TECHNOLOGY, vol. 12, no. 7, 1994, pages 699 - 702
CANCER RES., vol. 53, 1993, pages 851 - 856
BERNASCONI ET AL., SCIENCE, vol. 298, 2002, pages 2199 - 2202
SPRINGER ET AL., CELL, vol. 102, 2000, pages 275 - 277
KAWASAKI; KRETSINGER, PROTEIN PROF., vol. 2, 1995, pages 305 - 490
MONCRIEF ET AL., J. MOL. EVOL., vol. 30, 1990, pages 522 - 562
CHAUVAUX ET AL., BIOCHEM. J., vol. 265, 1990, pages 261 - 265
BAIROCH; COX, FEBS LETT., vol. 269, 1990, pages 454 - 456
DAVIS, NEW BIOL., vol. 2, 1990, pages 410 - 419
SCHAEFER ET AL., GENOMICS, vol. 25, 1995, pages 638 - 643
ECONOMOU ET AL., EMBO J., vol. 9, 1990, pages 349 - 354
WURZBURG ET AL., STRUCTURE, vol. 14, no. 6, 2006, pages 1049 - 1058
TOMLINSON ET AL., J. MOL. BIOL., vol. 227, 1992, pages 776 - 798
WILLIAMS; WINTER, EUR. J. LINMUNOL., vol. 23, 1993, pages 1456 - 1461
COX ET AL., NAT. GENETICS, vol. 7, 1994, pages 162 - 168
MATSUDA ET AL., J. EXP. MED., vol. 188, 1998, pages 1973 - 1975
KAWASAKI ET AL., EUR. J. IMMUNOL., vol. 31, 2001, pages 1017 - 1028
SCHABLE; ZACHAU, BIOL. CHEM. HOPPE SEYLER, vol. 374, 1993, pages 1001 - 1022
BRENSING-KUPPERS ET AL., GENE, vol. 191, 1997, pages 173 - 181
KAWASAKI ET AL., GENOME RES., vol. 7, 1997, pages 250 - 261
WU ET AL., J. EXP. MED., vol. 132, 1970, pages 211 - 250
KUNKEL ET AL., PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 488 - 492
KABAT: "Sequences of Proteins of Immunological Interest", 1987, NATIONAL INSTITUTE OF HEALTH BETHESDA MD.
LEE; RICHARDS, J. MOL. BIOL., vol. 55, 1971, pages 379 - 400
CONNOLLY, J. APPL. CRYST., vol. 16, 1983, pages 548 - 558
PACIOS, COMPUT. CHEM., vol. 18, no. 4, 1994, pages 377 - 386
J. MOL. MODEL., vol. 1, 1995, pages 46 - 53
GEJIMA ET AL., HUMAN ANTIBODIES, vol. 11, 2002, pages 121 - 129
CARDOSO ET AL., SCAND. J. HNMUNOL., vol. 51, 2000, pages 337 - 344
BIOORG. MED. CHEM., vol. 11, no. 17, 2003, pages 3761 - 2768
ANNU. REV. BIOPHYS. BIOMOL. STRUCT., vol. 35, 2006, pages 225 - 249
PROC. NATL. ACAD. SCI. U.S.A., vol. 100, no. 11, 2003, pages 6353 - 6357
CARDOSO ET AL., SCAND. J. IMMUNOL., vol. 51, 2000, pages 337 - 344
GHETIE, IMMUNOL. TODAY, vol. 18, no. 12, 1997, pages 592 - 598
RAGHAVAN ET AL., IMMUNITY, vol. 1, 1994, pages 303 - 315
THE JOURNAL OF IMMUNOLOGY, vol. 182, 2009, pages 7663 - 7671
"antigen-binding molecules are immobilized onto a chip, and human FcRn is poured as an analyte", THE JOURNAL OF IMMUNOLOGY, vol. 182, 2009, pages 7663 - 7671
CURR. OPIN. BIOTECHNOL., vol. 20, no. 6, 2009, pages 685 - 91
CURR. OPIN. IMMUNOL., vol. 20, no. 4, 2008, pages 460 - 470
PROTEIN ENG. DES. SEL., vol. 23, no. 4, 2010, pages 195 - 202
PROTEIN ENGINEERING, vol. 9, no. 3, 1996, pages 299 - 305
PROC. NATL. ACAD. SCI. USA, vol. 103, no. 11, 2006, pages 4005 - 4010
DAVIS ET AL., IMMUNOLOGICAL REVIEWS, vol. 190, 2002, pages 123 - 136
BURMEISTER ET AL., NATURE, vol. 372, 1994, pages 336 - 343
CURRENT OPINION IN BIOTECHNOLOGY, vol. 20, no. 6, 2009, pages 685 - 691
IMMUNITY, vol. 23, 2005, pages 503 - 514
MILSTEIN, NATURE, vol. 305, 1983, pages 537 - 540
RIDGWAY ET AL., PROTEIN ENGINEERING, vol. 9, 1996, pages 617 - 621
MERCHANT ET AL., NATURE BIOTECHNOLOGY, vol. 16, 1998, pages 677 - 681
J. PHARM. BIOMED. ANAL., vol. 55, no. 5, 2011, pages 878 - 888
CLIN. IMMUNOL., vol. 137, no. 1, 2010, pages 5 - 14
DRUGS RD., vol. 9, no. 6, 2008, pages 385 - 396
DRUG DISCOV TODAY, vol. 11, no. 1-2, 2006, pages 81 - 88
INT IMMUNOL., vol. 13, no. 12, 2001, pages 1551 - 1559
METHODS MOL BIOL., vol. 602, 2010, pages 93 - 104
CLIN PHARMACOL., vol. 48, no. 4, April 2008 (2008-04-01), pages 406 - 417
PHARM RES., vol. 23, no. 1, January 2006 (2006-01-01), pages 95 - 103
YANG ET AL., J. MOL. BIOL., vol. 254, 1995, pages 392 - 403
MARKS, BIO/TECHNOLOGY, vol. 10, 1992, pages 779 - 783
LOW, J. MOL. BIOL., vol. 250, 1996, pages 359 - 368
PATTEN, CURR. OPIN. BIOTECHNOL., vol. 8, 1997, pages 724 - 733
THOMPSON ET AL., J. MOL. BIOL., vol. 256, 1996, pages 77 - 88
CLAMERI ET AL., NATURE, vol. 391, 1998, pages 288 - 291
MILSTEIN ET AL., NATURE, vol. 305, 1983, pages 537 - 540
MERCHANT ET AL., NAT. BIOTECH., vol. 16, 1998, pages 677 - 681
J. IMMUNOTOXICOL., vol. 3, 2005, pages 131 - 139
MABS, vol. 2, no. 5, 2010, pages 1 - 13
ARTHRITIS & RHEUMATISM, vol. 54, 2006, pages 2387 - 2392
AAPS J., vol. 4, 2010, pages 646 - 657
BLOOD, vol. 112, no. 10, 2008, pages 3959 - 64
NAT. REV. IMMUNOL., vol. 7, no. 9, 2007, pages 715 - 25
SATO, K. ET AL., CANCER RES., vol. 53, no. 4, 1993, pages 851 - 856
NATURE, vol. 372, no. 6504, 1994, pages 379 - 383
J. BIOL. CHEM., vol. 276, no. 19, 2001, pages 16469 - 16477
J. IMMUNOL., vol. 166, no. 5, 2001, pages 3266 - 3276
J. IMMUNOL., vol. 187, no. 4, 2011, pages 1754 - 1763
METHODS MOL. BIOL., vol. 602, 2010, pages 93 - 104
HWANG ET AL., METHODS, vol. 36, 2005, pages 3 - 10
WALLE ET AL., EXPERT OPIN. BIO. THER., vol. 7, no. 3, 2007, pages 405 - 418
BRITISH JOURNAL OF CANCER, vol. 72, 1995, pages 1364 - 1372
SCAND. J. IMMUNOL., vol. 40, 1994, pages 457 - 465
J. PHARM. SCI., vol. 89, no. 3, 2000, pages 297 - 310
MOL. IMMUNOL., vol. 45, 2008, pages 3926 - 3933
PROTEIN SCIENCE, vol. 4, 1995, pages 2411 - 2423
J. IMMUNOL., vol. 152, 1994, pages 4958 - 4968
J. IMMUNOL. METHODS, vol. 332, no. 1-2, 2008, pages 2 - 9
J. IMMUNOL. METHODS, vol. 247, no. 1-2, 2001, pages 191 - 203
BIOTECHNOL. PROG., vol. 18, no. 2, 2002, pages 212 - 20
MOL. CELL PROTEOMICS, vol. 2, no. 2, 2003, pages 61 - 9
METHODS MOL. BIOL., vol. 178, 2002, pages 133 - 145
J. BIOL. CHEM., vol. 283, no. 37, 2008, pages 25140 - 25149
DALL' ACQUA ET AL., J. IMMUNOL., vol. 169, no. 9, 2002, pages 5171 - 5180
YEUNG ET AL., J. IMMUNOL., vol. 182, no. 12, 2009, pages 7663 - 7671
DATTA-MANNAN ET AL., J. BIOL. CHEM., vol. 282, no. 3, 2007, pages 1709 - 1717
DALL ACQUA ET AL., J. IMMUNOL., vol. 169, no. 9, 2002, pages 5171 - 5180
J. MOL. BIOL., vol. 296, 2000, pages 57 - 86
PROC. NATL. ACAD. SCI., vol. 106, no. 48, 2009, pages 20216 - 20221
KABAT, E.A. ET AL.: "Sequences of proteins of immunological interest", vol. 91, 1991, NIH PUBLICATION
METHODS MOL BIOL., vol. 178, 2002, pages 87 - 100
FEBS LETTER 11483, vol. 309, no. 1, pages 85 - 88
KABAT EA ET AL.: "Sequence of Proteins of Immunological Interest", 1991, NIH
NATURE, vol. 400, 2000, pages 267 - 273
J. BIOL. CHEM., vol. 276, 2011, pages 16469 - 16477
PROC. NATL. ACAD. SCI. USA, vol. 108, 2011, pages 12669 - 126674
J. IMUNOL., vol. 187, 2011, pages 3208 - 3217
PROTEIN SCIENCE, vol. 5, 1996, pages 2617 - 2622
See also references of EP 2698431A4
DALL'ACQUA W.F. ET AL.: "Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences.", J. IMMUNOL., vol. 169, no. 9, 1 November 2002 (2002-11-01), pages 5171 - 5180, XP002268422
JANICE M REICHERT; CLARK J ROSENSWEIG; LAURA B FADEN; MATTHEW C DEWITZ: "Monoclonal antibody successes in the clinic.", NAT. BIOTECHNOL., vol. 23, 2005, pages 1073 - 1078
PAVLOU AK; BELSEY MJ.: "The therapeutic antibodies market to 2008.", EUR J PHARM BIOPHARM., vol. 59, no. 3, 2005, pages 389 - 396
KIM SJ; PARK Y; HONG HJ.: "Antibody engineering for the development of therapeutic antibodies.", MOL CELLS, vol. 20, no. 1, 2005, pages 17 - 29
HINTON PR; XIONG JM; JOHLFS MG; TANG MT; KELLER S; TSURUSHITA N.: "An engineered human IgGI antibody with longer serum half-life.", J. IMMUNOL., vol. 176, no. 1, 2006, pages 346 - 356
GHETIE V; POPOV S; BORVAK J; RADU C; MATESOI D; MEDESAN C; OBER RJ; WARD ES.: "Increasing the serum persistence of an IgG fragment by random mutagenesis.", NAT. BIOTECHNOL., vol. 15, no. 7, 1997, pages 637 - 640
RAJPAL A; BEYAZ N; HABER L; CAPPUCCILLI G; YEE H; BHATT RR; TAKEUCHI T; LERNER RA; CREA R.: "A general method for greatly improving the affinity of antibodies by using combinatorial libraries", PROC. NATL. ACAD. SCI. U. S. A., vol. 102, no. 24, 2005, pages 8466 - 8471
WU H; PFARR DS; JOHNSON S; BREWAH YA; WOODS RM; PATEL NK; WHITE WI; YOUNG JF; KIENER PA.: "Development of Motavizumab, an Ultra-potent Antibody for the Prevention of Respiratory Syncytial Virus Infection in the Upper and Lower Respiratory Tract.", J. MOL. BIOL., vol. 368, 2007, pages 652 - 665
HANSON CV; NISHIYAMA Y; PAUL S.: "Catalytic antibodies and their applications", CURR OPIN BIOTECHNOL., vol. 16, no. 6, 2005, pages 631 - 636
RATHANASWAMI P; ROALSTAD S; ROSKOS L; SU QJ; LACKIE S; BABCOOK J.: "Demonstration of an in vivo generated sub-picomolar affinity fully human monoclonal antibody to interleukin-8", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 334, no. 4, 2005, pages 1004 - 1013
DALL'ACQUA WF; WOODS RM; WARD ES; PALASZYNSKI SR; PATEL NK; BREWAH YA; WU H; KIENER PA; LANGERMANN S.: "Increasing the affinity of a human IgG for the neonatal Fc receptor: biological consequences", J. IMMUNOL., vol. 169, no. 9, 2002, pages 5171 - 5180
YEUNG YA; LEABMAN MK; MARVIN JS; QIU J; ADAMS CW; LIEN S; STAROVASNIK MA; LOWMAN HB.: "Engineering human IgGl affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates", J. IMMUNOL., vol. 182, no. 12, 2009, pages 7663 - 7671
DATTA-MANNAN A; WITCHER DR; TANG Y; WATKINS J; WROBLEWSKI VJ.: "Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor.", J. BIOL. CHEM., vol. 282, no. 3, 2007, pages 1709 - 1717
NIEBECKER R; KLOFT C.: "Safety of therapeutic monoclonal antibodies", CURR. DRUG SAF., vol. 5, no. 4, 2010, pages 275 - 286
JEFFERIS R; LUND J.: "Interaction sites on human IgG-Fc for FcgammaR: current models", IMMUNOL. LETT., vol. 82, 2002, pages 57 - 65
NIMMERJAHN F; RAVETCH JV: "Fcgamma receptors as regulators of immune responses", NAT. REV. IMMUNOL., vol. 8, no. 1, 2008, pages 34 - 47
M. CLARK: "Antibody Engineering IgG Effector Mechanisms", CHEMICAL IMMUNOLOGY, vol. 65, 1997, pages 88 - 110
GREENWOOD J; CLARK M; WALDMANN H.: "Structural motifs involved in human IgG antibody effector functions", EUR. J. IMMUNOL., vol. 23, 1993, pages 1098 - 1104
AMIGORENA S; BONNEROT C; CHOQUET D; FRIDMAN WH; TEILLAUD JL.: "Fc gamma RII expression in resting and activated B lymphocytes", EUR. J. IMMUNOL., vol. 19, 1989, pages 1379 - 1385
NICHOLAS R; SINCLAIR SC: "Regulation of the immune response. I. Reduction in ability of specific antibody to inhibit long-lasting IgG immunological priming after removal of the Fc fragment", J. EXP. MED., vol. 129, 1969, pages 1183 - 1201
HEYMAN B.: "Feedback regulation by IgG antibodies", IMMUNOL. LETT., vol. 88, 2003, pages 157 - 161
S AMIGORENA; C BONNEROT; DRAKE, JR; D CHOQUET; W HUNZIKER; JG GUILLET; P WEBSTER; C SAUTES; I MELLMAN; WH FRIDMAN: "Cytoplasmic domain heterogeneity and functions of IgG Fc receptors in B lymphocytes", SCIENCE, vol. 256, 1992, pages 1808 - 1812
MUTA, T.; KUROSAKI, T.; MISULOVIN, Z.; SANCHEZ, M.; NUSSENZWEIG, M. C.; RAVETCH, J. V: "A 13-amino-acid motif in the cytoplasmic domain ofFcyRIIB modulates B-cell receptor signaling", NATURE, vol. 368, 1994, pages 70 - 73
RAVETCH JV; LANIER LL.: "Immune inhibitory receptors", SCIENCE, vol. 290, 2000, pages 84 - 89
LIANG Y; QIU H; GLINKA Y; LAZARUS AH; NI H; PRUD'HOMME GJ; WANG Q.: "Immunity against a therapeutic xenoprotein/Fc construct delivered by gene transfer is reduced through binding to the inhibitory receptor FcyRIIb", J. GENE MED., 2011
SMITH KG; CLATWORTHY MR.: "FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications", NAT. REV. IMMUNOL., vol. 10, 2010, pages 328 - 343
WERNERSSON S; KARLSSON MC; DAHLSTROM J; MATTSSON R; VERBEEK JS; HEYMAN B.: "IgG-mediated enhancement of antibody responses is low in Fc receptor gamma chain-deficient mice and increased in Fc gamma RII-deficient mice", J. IMMUNOL., vol. 163, 1999, pages 618 - 622
JOACHIM L. SCHULTZE; SABINE MICHALAK; JOEL LOWNE; ADAM WONG; MARIA H. GILLEECE; JOHN G. GRIBBEN; LEE M. NADLER: "Human Non-Germinal Center B Cell Interleukin (IL)-12 Production Is Primarily Regulated by T Cell Signals CD40 Ligand, Interferon y, and IL-10: Role of B Cells in the Maintenance ofT Cell Responses", J. EXP. MED., vol. 189, 1999, pages 187 - 194
NAKAMURA, A.; YUASA, T.; UJIKE, A.; ONO, M.; NUKIWA, T.; RAVETCH, J.V; TAKAI, T.: "Fcy receptor IIB-deficient mice develop Goodpasture's syndrome upon immunization with type IV collagen: A novel murine model for autoimmune glomerular basement membrane disease", J. EXP. MED., vol. 191, 2000, pages 899 - 906
BLANK MC; STEFANESCU RN; MASUDA E; MARTI F; KING PD; REDECHA PB; WURZBURGER RJ; PETERSON MG; TANAKA S; PRICOP L.: "Decreased transcription of the human FCGR2B gene mediated by the -343 G/C promoter polymorphism and association with systemic lupus erythematosus", HUM. GENET., vol. 117, 2005, pages 220 - 227
OLFERIEV M; MASUDA E; TANAKA S; BLANK MC; PRICOP L.: "The Role of Activating Protein 1 in the Transcriptional Regulation of the Human FCGR2B Promoter Mediated by the -343 G ->C Polymorphism Associated with Systemic Lupus Erythematosus", J. BIOL. CHEM., vol. 282, 2007, pages 1738 - 1746
LV J; YANG Y; ZHOU X; YU L; LI R; HOU P; ZHANG H: "FCGR3B copy number variation is not associated with lupus nephritis in a Chinese population", ARTHRITIS RHEUM., vol. 54, 2006, pages 3908 - 3917
FLOTO RA; CLATWORTHY MR; HEILBRONN KR; ROSNER DR; MACARY PA; RANKIN A; LEHNER PJ; OUWEHAND WH; ALLEN JM; WATKINS NA: "Loss of function of a lupus-associated FcgammaRIIb polymorphism through exclusion from lipid rafts", NAT. MED., vol. 11, 2005, pages 1056 - 1058
LI DH; TUNG JW; TAMER IH; SNOW AL; YUKINARI T; NGERNMANEEPOTHONG R; MARTINEZ OM; PARNES JR.: "CD72 Down-Modulates BCR-Induced Signal Transduction and Diminishes Survival in Primary Mature B Lymphocytes", J. IMMUNOL., vol. 176, 2006, pages 5321 - 5328
MACKAY M; STANEVSKY A; WANG T; ARANOW C; LI M; KOENIG S; RAVETCH JV; DIAMOND B.: "Selective dysregulation of the FcgammaIIB receptor on memory B cells in SLE.", J. EXP. MED., vol. 203, 2006, pages 2157 - 2164
SU K; YANG H; LI X; LI X; GIBSON AW; CAFARDI JM; ZHOU T; EDBERG JC; KIMBERLY RP.: "Expression profile ofFcgammaRIIb on leukocytes and its dysregulation in systemic lupus erythematosus", J. IMMUNOL., vol. 178, 2007, pages 3272 - 3280
BRUHNS P; IANNASCOLI B; ENGLAND P; MANCARDI DA; FERNANDEZ N; JORIEUX S; DAËRON M.: "Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses", BLOOD, vol. 113, 2009, pages 3716
CHU SY; VOSTIAR I; KARKI S; MOORE GL; LAZAR GA; PONG E; JOYCE PF; SZYMKOWSKI DE; DESJARLAIS JR.: "Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD 19 and FcgammaRlIb with Fc-engineered antibodies", MOL. IMMUNOL., vol. 45, 2008, pages 3926 - 3933
WARMERDAM PA; VAN DE WINKEL JG; GOSSELIN EJ; CAPEL PJ.: "Molecular basis for a polymorphism of human Fc gamma receptor II (CD32", J. EXP. MED., vol. 172, 1990, pages 19 - 25
ARMOUR, KL; VAN DE WINKEL, JG; WILLIAMSON, LM; CLARK, MR.: "Differential binding to human FcgammaRIIa and FcgammaRIIb receptors by human IgG wildtype and mutant antibodies", MOL. IMMUNOL., vol. 40, 2003, pages 585 - 593
SCIENCE TRANSLATIONAL MEDICINE, vol. 2, no. 47, 2010, pages 47RA63
SALMON JE; MILLARD S; SCHACHTER LA; ARNETT FC; GINZLER EM; GOURLEY MF; RAMSEY-GOLDMAN R; PETERSON MG; KIMBERLY RP.: "Fc gamma RIIA alleles are heritable risk factors for lupus nephritis in African Americans", J. CLIN. INVEST., vol. 97, 1996, pages 1348 - 1354
MANGER K; REPP R; SPRIEWALD BM; RASCU A; GEIGER A; WASSMUTH R; WESTERDAAL NA; WENTZ B; MANGER B; KALDEN JR: "Fcgamma receptor IIa polymorphism in Caucasian patients with systemic lupus erythematosus: association with clinical symptoms", ARTHRITIS RHEUM., vol. 41, 1998, pages 1181 - 1189
QIAO SW; KOBAYASHI K; JOHANSEN FE; SOLLID LM; ANDERSEN JT; MILFORD E; ROOPENIAN DC; LENCER WI; BLUMBERG RS.: "Dependence of antibody-mediated presentation of antigen on FcRn.", PROC. NATL. ACAD. SCI., vol. 105, no. 27, 2008, pages 9337 - 9342
MI W; WANJIE S; LO ST; GAN Z; PICKL-HERK B; OBER RJ; WARD ES: "Targeting the neonatal fc receptor for antigen delivery using engineered fc fragments", J. IMMUNOL., vol. 181, no. 11, 2008, pages 7550 - 7561
"Epitope Mapping Protocols in Methods in Molecular Biology", vol. 66, 1996
ED HARLOW; DAVID LANE: "Antibodies: A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY, pages: 359 - 420
MULLBERG ET AL., J. IMMUNOL., vol. 152, no. 10, 1994, pages 4958 - 4968
SAMBROOK, J ET AL.: "Molecular Cloning", 1989, COLD SPRING HARBOR LAB. PRESS, pages: 9.47 - 9.58
J. IMMUNOL., vol. 123, no. 4, 1979, pages 1548 - 1550
CURRENT TOPICS IN MICROBIOLOGY AND IMMUNOLOGY, vol. 81, 1978, pages 1 - 7
C. EUR. J. IMMUNOL., vol. 6, no. 7, 1976, pages 511 - 519
CELL, vol. 8, no. 3, 1976, pages 405 - 415
NATURE, vol. 276, no. 5685, 1978, pages 269 - 270
J. IMMUNOL. METHODS, vol. 35, no. 1-2, 1980, pages 1 - 21
J. EXP. MED., vol. 148, no. 1, 1978, pages 313 - 323
NATURE, vol. 277, no. 5692, 1979, pages 131 - 133
KOHLER; MILSTEIN, METHODS ENZYMOL., vol. 73, 1981, pages 3 - 46
VANDAMME ET AL., EUR. J. BIOCHEM., vol. 192, no. 3, 1990, pages 767 - 775
BIOCHEMISTRY, vol. 18, no. 24, 1979, pages 5294 - 5299
ANAL. BIOCHEM., vol. 162, no. 1, 1987, pages 156 - 159
PROC. NATL. ACAD. SCI. USA, vol. 85, no. 23, 1988, pages 8998 - 9002
NUCLEIC ACIDS RES., vol. 17, no. 8, 1989, pages 2919 - 2932
EBERT, K. M. ET AL., BIO/TECHNOLOGY, vol. 12, no. 7, 1994, pages 699 - 702
CANCER RES., vol. 53, 1993, pages 851 - 856
BERNASCONI ET AL., SCIENCE, vol. 298, 2002, pages 2199 - 2202
SPRINGER ET AL., CELL, vol. 102, 2000, pages 275 - 277
KAWASAKI; KRETSINGER, PROTEIN PROF., vol. 2, 1995, pages 305 - 490
MONCRIEF ET AL., J. MOL. EVOL., vol. 30, 1990, pages 522 - 562
CHAUVAUX ET AL., BIOCHEM. J., vol. 265, 1990, pages 261 - 265
BAIROCH; COX, FEBS LETT., vol. 269, 1990, pages 454 - 456
DAVIS, NEW BIOL., vol. 2, 1990, pages 410 - 419
SCHAEFER ET AL., GENOMICS, vol. 25, 1995, pages 638 - 643
ECONOMOU ET AL., EMBO J., vol. 9, 1990, pages 349 - 354
WURZBURG ET AL., STRUCTURE, vol. 14, no. 6, 2006, pages 1049 - 1058
TOMLINSON ET AL., J. MOL. BIOL., vol. 227, 1992, pages 776 - 798
WILLIAMS; WINTER, EUR. J. LINMUNOL., vol. 23, 1993, pages 1456 - 1461
COX ET AL., NAT. GENETICS, vol. 7, 1994, pages 162 - 168
MATSUDA ET AL., J. EXP. MED., vol. 188, 1998, pages 1973 - 1975
KAWASAKI ET AL., EUR. J. IMMUNOL., vol. 31, 2001, pages 1017 - 1028
SCHABLE; ZACHAU, BIOL. CHEM. HOPPE SEYLER, vol. 374, 1993, pages 1001 - 1022
BRENSING-KUPPERS ET AL., GENE, vol. 191, 1997, pages 173 - 181
KAWASAKI ET AL., GENOME RES., vol. 7, 1997, pages 250 - 261
WU ET AL., J. EXP. MED., vol. 132, 1970, pages 211 - 250
KUNKEL ET AL., PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 488 - 492
KABAT: "Sequences of Proteins of Immunological Interest", 1987, NATIONAL INSTITUTE OF HEALTH BETHESDA MD.
LEE; RICHARDS, J. MOL. BIOL., vol. 55, 1971, pages 379 - 400
CONNOLLY, J. APPL. CRYST., vol. 16, 1983, pages 548 - 558
PACIOS, COMPUT. CHEM., vol. 18, no. 4, 1994, pages 377 - 386
J. MOL. MODEL., vol. 1, 1995, pages 46 - 53
GEJIMA ET AL., HUMAN ANTIBODIES, vol. 11, 2002, pages 121 - 129
CARDOSO ET AL., SCAND. J. HNMUNOL., vol. 51, 2000, pages 337 - 344
BIOORG. MED. CHEM., vol. 11, no. 17, 2003, pages 3761 - 2768
ANNU. REV. BIOPHYS. BIOMOL. STRUCT., vol. 35, 2006, pages 225 - 249
PROC. NATL. ACAD. SCI. U.S.A., vol. 100, no. 11, 2003, pages 6353 - 6357
CARDOSO ET AL., SCAND. J. IMMUNOL., vol. 51, 2000, pages 337 - 344
GHETIE, IMMUNOL. TODAY, vol. 18, no. 12, 1997, pages 592 - 598
RAGHAVAN ET AL., IMMUNITY, vol. 1, 1994, pages 303 - 315
THE JOURNAL OF IMMUNOLOGY, vol. 182, 2009, pages 7663 - 7671
"antigen-binding molecules are immobilized onto a chip, and human FcRn is poured as an analyte", THE JOURNAL OF IMMUNOLOGY, vol. 182, 2009, pages 7663 - 7671
CURR. OPIN. BIOTECHNOL., vol. 20, no. 6, 2009, pages 685 - 91
CURR. OPIN. IMMUNOL., vol. 20, no. 4, 2008, pages 460 - 470
PROTEIN ENG. DES. SEL., vol. 23, no. 4, 2010, pages 195 - 202
PROTEIN ENGINEERING, vol. 9, no. 3, 1996, pages 299 - 305
PROC. NATL. ACAD. SCI. USA, vol. 103, no. 11, 2006, pages 4005 - 4010
DAVIS ET AL., IMMUNOLOGICAL REVIEWS, vol. 190, 2002, pages 123 - 136
BURMEISTER ET AL., NATURE, vol. 372, 1994, pages 336 - 343
CURRENT OPINION IN BIOTECHNOLOGY, vol. 20, no. 6, 2009, pages 685 - 691
IMMUNITY, vol. 23, 2005, pages 503 - 514
MILSTEIN, NATURE, vol. 305, 1983, pages 537 - 540
RIDGWAY ET AL., PROTEIN ENGINEERING, vol. 9, 1996, pages 617 - 621
MERCHANT ET AL., NATURE BIOTECHNOLOGY, vol. 16, 1998, pages 677 - 681
J. PHARM. BIOMED. ANAL., vol. 55, no. 5, 2011, pages 878 - 888
CLIN. IMMUNOL., vol. 137, no. 1, 2010, pages 5 - 14
DRUGS RD., vol. 9, no. 6, 2008, pages 385 - 396
DRUG DISCOV TODAY, vol. 11, no. 1-2, 2006, pages 81 - 88
INT IMMUNOL., vol. 13, no. 12, 2001, pages 1551 - 1559
METHODS MOL BIOL., vol. 602, 2010, pages 93 - 104
CLIN PHARMACOL., vol. 48, no. 4, April 2008 (2008-04-01), pages 406 - 417
PHARM RES., vol. 23, no. 1, January 2006 (2006-01-01), pages 95 - 103
YANG ET AL., J. MOL. BIOL., vol. 254, 1995, pages 392 - 403
MARKS, BIO/TECHNOLOGY, vol. 10, 1992, pages 779 - 783
LOW, J. MOL. BIOL., vol. 250, 1996, pages 359 - 368
PATTEN, CURR. OPIN. BIOTECHNOL., vol. 8, 1997, pages 724 - 733
THOMPSON ET AL., J. MOL. BIOL., vol. 256, 1996, pages 77 - 88
CLAMERI ET AL., NATURE, vol. 391, 1998, pages 288 - 291
MILSTEIN ET AL., NATURE, vol. 305, 1983, pages 537 - 540
MERCHANT ET AL., NAT. BIOTECH., vol. 16, 1998, pages 677 - 681
J. IMMUNOTOXICOL., vol. 3, 2005, pages 131 - 139
MABS, vol. 2, no. 5, 2010, pages 1 - 13
ARTHRITIS & RHEUMATISM, vol. 54, 2006, pages 2387 - 2392
AAPS J., vol. 4, 2010, pages 646 - 657
BLOOD, vol. 112, no. 10, 2008, pages 3959 - 64
NAT. REV. IMMUNOL., vol. 7, no. 9, 2007, pages 715 - 25
SATO, K. ET AL., CANCER RES., vol. 53, no. 4, 1993, pages 851 - 856
NATURE, vol. 372, no. 6504, 1994, pages 379 - 383
J. BIOL. CHEM., vol. 276, no. 19, 2001, pages 16469 - 16477
J. IMMUNOL., vol. 166, no. 5, 2001, pages 3266 - 3276
J. IMMUNOL., vol. 187, no. 4, 2011, pages 1754 - 1763
METHODS MOL. BIOL., vol. 602, 2010, pages 93 - 104
HWANG ET AL., METHODS, vol. 36, 2005, pages 3 - 10
WALLE ET AL., EXPERT OPIN. BIO. THER., vol. 7, no. 3, 2007, pages 405 - 418
BRITISH JOURNAL OF CANCER, vol. 72, 1995, pages 1364 - 1372
SCAND. J. IMMUNOL., vol. 40, 1994, pages 457 - 465
J. PHARM. SCI., vol. 89, no. 3, 2000, pages 297 - 310
MOL. IMMUNOL., vol. 45, 2008, pages 3926 - 3933
PROTEIN SCIENCE, vol. 4, 1995, pages 2411 - 2423
J. IMMUNOL., vol. 152, 1994, pages 4958 - 4968
J. IMMUNOL. METHODS, vol. 332, no. 1-2, 2008, pages 2 - 9
J. IMMUNOL. METHODS, vol. 247, no. 1-2, 2001, pages 191 - 203
BIOTECHNOL. PROG., vol. 18, no. 2, 2002, pages 212 - 20
MOL. CELL PROTEOMICS, vol. 2, no. 2, 2003, pages 61 - 9
METHODS MOL. BIOL., vol. 178, 2002, pages 133 - 145
J. BIOL. CHEM., vol. 283, no. 37, 2008, pages 25140 - 25149
DALL' ACQUA ET AL., J. IMMUNOL., vol. 169, no. 9, 2002, pages 5171 - 5180
YEUNG ET AL., J. IMMUNOL., vol. 182, no. 12, 2009, pages 7663 - 7671
DATTA-MANNAN ET AL., J. BIOL. CHEM., vol. 282, no. 3, 2007, pages 1709 - 1717
DALL ACQUA ET AL., J. IMMUNOL., vol. 169, no. 9, 2002, pages 5171 - 5180
J. MOL. BIOL., vol. 296, 2000, pages 57 - 86
PROC. NATL. ACAD. SCI., vol. 106, no. 48, 2009, pages 20216 - 20221
KABAT, E.A. ET AL.: "Sequences of proteins of immunological interest", vol. 91, 1991, NIH PUBLICATION
METHODS MOL BIOL., vol. 178, 2002, pages 87 - 100
FEBS LETTER 11483, vol. 309, no. 1, pages 85 - 88
KABAT EA ET AL.: "Sequence of Proteins of Immunological Interest", 1991, NIH
NATURE, vol. 400, 2000, pages 267 - 273
J. BIOL. CHEM., vol. 276, 2011, pages 16469 - 16477
PROC. NATL. ACAD. SCI. USA, vol. 108, 2011, pages 12669 - 126674
J. IMUNOL., vol. 187, 2011, pages 3208 - 3217
PROTEIN SCIENCE, vol. 5, 1996, pages 2617 - 2622
See also references of EP 2698431A4
Attorney, Agent or Firm:
SHIMIZU, Hatsushi et al. (JP)
Spring water Original aim (JP)
Spring water Original aim (JP)
Download PDF:
Claims: